An analysis of randomized trials indicates that use of inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease (COPD) does not improve the rate of survival after one year, but is associated with an increased risk of pneumonia, according to an article in the November 26 issue of JAMA.

It is well known that patients with chronic obstructive pulmonary disease (COPD) frequently suffer from depression and anxiety, but according to new research, depression and anxiety may actually cause increased hospitalizations and exacerbations.

In the first study to directly examine the effects of beta-blockers on surgical patients with chronic obstructive pulmonary disease (COPD), researchers have found that, contrary to previous thought, beta-blockers significantly reduce mortality in COPD patients.

A common bronchodilator drug which has been used for more than a decade by patients with chronic obstructive pulmonary disease (COPD) has been linked to a one-third higher risk of cardiovascular-related deaths.

For the first time, researchers have demonstrated a close correlation between the decline in a key component of the lung's antioxidant defense system and the progression of chronic obstructive pulmonary disease (COPD) in humans.

You know it's good for you in other ways, but could eating your broccoli also help patients with chronic lung disease? It just might.

Creatine, a popular nutritional supplement renowned for enhancing athletic performance and muscle strength, does not improve exercise outcomes in patients with chronic obstructive pulmonary disease (COPD), according to a new study.

Data presented today at the International Conference of the American Thoracic Society (ATS) demonstrate that concomitant therapy of chronic obstructive pulmonary disease with Perforomist™ Inhalation Solution (formoterol fumarate inhalation solution; FFIS), delivered by nebulization, and Spiriva® (tiotropium; TIO) is significantly more effective than treatment with tiotropium alone.

Patients with chronic obstructive pulmonary disease (COPD) who are in their final years of survival do not get the same benefits from pulmonary rehabilitation (PR) as patients who have more years left to live—regardless of their age, complicating illnesses or lung function, according to new research funded by the Veteran’s Administration, which will be presented at the American Thoracic Society’s 2008 International Conference in Toronto on Tuesday, May 20.

Researchers at Washington University School of Medicine in St. Louis have defined a new type of immune response that is activated in patients with severe asthma and COPD (chronic obstructive pulmonary disease). Their discovery could dramatically improve diagnosis and treatment of patients with chronic inflammatory lung disease.

Applied Data Research Analyzes Emerging Therapeutics and Technologies for Chronic Obstructive Pulmonary Disease

Engine exhaust fumes are linked to excess deaths from pneumonia across England, suggests research published in the Journal of Epidemiology and Community Health.